In our meta-analysis, dual immunotherapy and ICI+anti-VEGFR/VEGFA did not increase the incidence of hepatotoxicity compared to monotherapy, and because of their better survival benefit, they can be prioritized as a priority for HCC patients in the clinic. Here, VEGFA is linked to hepatocellular carcinoma.